The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report.
A 23-year-old woman with a nine-month history of SLE, uncontrolled with high daily doses of steroids, was treated with the T-cell immunostimulant drug, levamisole. Following a single oral three-day course of therapy with this agent her immunologic parameters and clinical manifestations underwent marked regression. Continuous two-weekly course of this drug at three days per course have allowed rapid reduction of her steroid and resulted in complete remission of her symptoms. The theoretical considerations for the use of levamisole dovetailed perfectly with the observed response to this agent.
D000328:Adult; D000367:Age Factors; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007978:Levamisole / Q000494:pharmacology / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects; D012737:Sex Factors; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
D007978:Levamisole